Evidence map›Paper›PMID 40820392›Full record

ReviewInnate immunity

Engineered neutrophil, an emerging immune therapeutic strategy.

Jingyi Wang, Teng Deng, Ruisi Chen, Lu Yang, Yan Teng, Junming Miao

Abstract readReview
In one paragraph

Review in Innate immunity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingyi WangDepartmnent of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, PR China.
Teng DengDepartmnent of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, PR China.
Ruisi ChenDepartmnent of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, PR China.
Lu YangDepartmnent of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, PR China.
Yan TengDepartmnent of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, PR China.ORCID 0000-0002-8850-251X
Junming MiaoDepartmnent of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophils play a pivotal role in the host immune system, serving as the frontline defense against microbial infections. They eradicate pathogens through diverse mechanisms, encompassing degranulation, phagocytosis, and the release of reactive oxygen species. Moreover, they are acknowledged as crucial contributors to chronic inflammatory pathological processes, including conditions such as cancer and autoimmune diseases. An expanding body of research suggests that neutrophils, harnessing their innate immune characteristics, possess the potential to serve as carriers for therapeutic agents or be directly employed in disease treatment. This underscores their potential as a cell therapy platform for future applications. Consequently, we systematically investigate the potential applications of neutrophils in this review, with a primary emphasis on elucidating the research advancements in utilizing neutrophils, including those derived from stem cells, for therapeutic interventions in various diseases.

Indexed as

Autoimmune DiseasesImmunotherapyInflammationNeoplasmsNeutrophilsAnimalsHumansImmunity, InnatePhagocytosisdrug deliveryNeutrophiltransfusion

Identifiers

PMID40820392
PMCPMC12361729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.